PCM
KNSA icon

Polymer Capital Management’s Kiniksa Pharmaceuticals KNSA Stock Holding History

Polymer Capital Management’s Portfolio KNSA Stock Details KNSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,486
Closed -$290K – 861
2025
Q2 		$290K Buy
10,486
+1,344
+15% +$34.2K 0.03% 436
2025
Q1 		$203K Buy
+9,142
New +$188K 0.05% 436

Other funds holding KNSA

RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Polymer Capital Management's KNSA Position: Q3 2025 in Review

Polymer Capital Management sold out of Kiniksa Pharmaceuticals (KNSA) in Q3 2025, closing a stake of 10,486 shares — an estimated $290K sold.

Polymer Capital Management first reported a position in KNSA in Q1 2025 and held it in 2 quarters. The position peaked at $290K in Q2 2025. 204 funds tracked by Wall St. Rank hold KNSA as of Q3 2025.

  • Polymer Capital Management reported no remaining Kiniksa Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Polymer Capital Management sold 10,486 Kiniksa Pharmaceuticals shares in Q3 2025, an estimated $290K.
  • Polymer Capital Management first reported a position in Kiniksa Pharmaceuticals in Q1 2025 and held it in 2 quarters.
  • Polymer Capital Management's Kiniksa Pharmaceuticals position peaked at $290K in Q2 2025.
  • 204 funds tracked by Wall St. Rank held Kiniksa Pharmaceuticals as of Q3 2025.

Based on Polymer Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.